Document Detail


Pilot study on the use of a two-week course of oral misoprostol in patients after termination of pregnancy with mifepristone and misoprostol.
MedLine Citation:
PMID:  9589834     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Twenty women who requested early first trimester termination of pregnancy were recruited to study the tolerability of a 2-week course of oral misoprostol after termination of pregnancy by mifepristone and vaginal misoprostol. Ten patients (50%) complained of mild diarrhea during the 2-week course of misoprostol. Otherwise, there were no other significant side effects. The 2-week course of misoprostol was well tolerated by women who underwent early first trimester termination of pregnancy with mifepristone and misoprostol.
A pilot study was conducted to assess whether prolonged use of misoprostol is well tolerated by women who have undergone termination of an early pregnancy with mifepristone and misoprostol and if this regimen increases the complete abortion rate and decreases the duration of bleeding. Enrolled were 20 women from Hong Kong and Shanghai with a menstrual delay of 21 days or less; the mean duration of pregnancy was 40.8 +or- 4.7 days. Women were given 200 mg of oral mifepristone, followed 48 hours later by 400 mcg of vaginal misoprostol. Oral misoprostol (400 mcg) was continued twice daily for 2 weeks. 11 women (55%) aborted during the initial 4-hour observation period and all had complete abortion. The mean duration of bleeding was 25.2 +or- 4.3 days. Nausea, diarrhea, and lower abdominal pain were the most common side effects of misoprostol, but all women were able to complete the 2-week course of treatment. On the basis of the findings of this pilot study, a prospective, randomized study with a larger number of patients is recommended to confirm whether a 2-week course of misoprostol can increase the abortion rate and decrease the duration of postabortal bleeding.
Authors:
O S Tang; P P Gao; L Cheng; S Lee; P C Ho
Related Documents :
4033154 - Speculations on the origin of the ill-effects associated with the use of visual display...
9080204 - Clinical uses of antiprogestogens.
2918074 - Efficacy of the antiprogestin mifepristone (ru 486) prior to prostaglandin termination ...
16945904 - Climatically driven emissions of hydrocarbons from marine sediments during deglaciation.
9646094 - Toxoplasmic retinochoroiditis: resolution without treatment of the perilesional satelli...
11925374 - The diaphragm with and without spermicide for contraception: a cochrane review.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Contraception     Volume:  57     ISSN:  0010-7824     ISO Abbreviation:  Contraception     Publication Date:  1998 Feb 
Date Detail:
Created Date:  1998-07-13     Completed Date:  1998-07-13     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0234361     Medline TA:  Contraception     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  89-91     Citation Subset:  IM; J    
Affiliation:
Department of Obstetrics and Gynaecology, University of Hong Kong.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Abortifacient Agents, Nonsteroidal*
Abortifacient Agents, Steroidal*
Abortion, Induced*
Administration, Intravaginal
Adolescent
Adult
Diarrhea / chemically induced
Female
Gestational Age
Humans
Mifepristone*
Misoprostol / administration & dosage,  adverse effects*
Parity
Pilot Projects
Pregnancy
Chemical
Reg. No./Substance:
0/Abortifacient Agents, Nonsteroidal; 0/Abortifacient Agents, Steroidal; 59122-46-2/Misoprostol; 84371-65-3/Mifepristone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Oral methotrexate and vaginal misoprostol for early abortion.
Next Document:  Prevalence and clinical correlates of unsuccessful use of drugs to induce menstruation.